BR112018067808A2 - preparação medicinal líquida - Google Patents

preparação medicinal líquida

Info

Publication number
BR112018067808A2
BR112018067808A2 BR112018067808A BR112018067808A BR112018067808A2 BR 112018067808 A2 BR112018067808 A2 BR 112018067808A2 BR 112018067808 A BR112018067808 A BR 112018067808A BR 112018067808 A BR112018067808 A BR 112018067808A BR 112018067808 A2 BR112018067808 A2 BR 112018067808A2
Authority
BR
Brazil
Prior art keywords
medicinal preparation
liquid medicinal
polyhydric alcohol
present
liquid
Prior art date
Application number
BR112018067808A
Other languages
English (en)
Other versions
BR112018067808B1 (pt
Inventor
Tanisaka Hiroki
Murakami Tatsuya
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of BR112018067808A2 publication Critical patent/BR112018067808A2/pt
Publication of BR112018067808B1 publication Critical patent/BR112018067808B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

um objetivo da presente invenção é fornecer uma preparação medicinal líquida que não gere precipitados e seja adequada para produção em massa. de acordo com a presente invenção, é fornecida uma preparação medicinal líquida que contém 1-(2-desóxi-2-fluoro-4-tio-ß-d-arabinofuranosil)citosina ou um sal desta, um álcool poli-hídrico tendo um peso molecular de 100 ou menos, e água. o álcool poli-hídrico é preferivelmente glicerina, propileno glicol ou butanodiol.
BR112018067808-2A 2016-02-29 2017-02-28 Preparação medicinal líquida BR112018067808B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016-037309 2016-02-29
JP2016037309 2016-02-29
JP2016208563A JP6450356B2 (ja) 2016-02-29 2016-10-25 液状医薬製剤
JP2016-208563 2016-10-25
PCT/JP2017/007720 WO2017150511A1 (ja) 2016-02-29 2017-02-28 液状医薬製剤

Publications (2)

Publication Number Publication Date
BR112018067808A2 true BR112018067808A2 (pt) 2019-01-15
BR112018067808B1 BR112018067808B1 (pt) 2024-01-02

Family

ID=59808127

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067808-2A BR112018067808B1 (pt) 2016-02-29 2017-02-28 Preparação medicinal líquida

Country Status (12)

Country Link
US (1) US11382927B2 (pt)
EP (1) EP3424509B1 (pt)
JP (1) JP6450356B2 (pt)
KR (1) KR102160866B1 (pt)
CN (1) CN108697726B (pt)
AU (1) AU2017227280B2 (pt)
BR (1) BR112018067808B1 (pt)
CA (1) CA3016020C (pt)
HK (1) HK1257435A1 (pt)
RU (1) RU2715240C1 (pt)
TW (1) TWI752940B (pt)
WO (1) WO2017150511A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641009B (zh) 2016-08-31 2021-12-31 富士胶片株式会社 抗肿瘤剂、抗肿瘤效果增强剂及抗肿瘤用试剂盒
MX2018002611A (es) 2018-01-29 2019-07-30 Fujifilm Corp Agente antitumoral para cancer del tracto biliar y metodo para tratar cancer del tracto biliar.
CA3110224A1 (en) * 2018-09-25 2020-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
WO2023008511A1 (ja) 2021-07-29 2023-02-02 富士フイルム株式会社 Ｂａｐ１およびｐｂｒｍ１の少なくとも１つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69715774T2 (de) * 1996-04-09 2003-05-15 Yamasa Corp 1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)-cytosine
JP2004339172A (ja) * 2003-05-19 2004-12-02 Taiyo Yakuhin Kogyo Kk 注射用液状医薬製剤
WO2007130783A2 (en) 2006-05-03 2007-11-15 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
WO2008087558A2 (en) * 2007-01-17 2008-07-24 Institut De Recherches Cliniques De Montreal Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
CN101402662B (zh) * 2008-11-07 2011-06-15 江苏奥赛康药业有限公司 一种奈拉滨的制备方法
BRPI1010809A2 (pt) * 2009-05-12 2015-10-13 Southern Res Inst composto, composição farmacêutica, métodos de tratar câncer em mamífero e usos de compostos e de composição farmacêutica
CN101642569A (zh) * 2009-08-31 2010-02-10 杭州双马生物工程有限公司 活性天然产物b用于制备抗真菌抗肿瘤产品的用途
CN102656154B (zh) 2009-12-18 2014-04-09 天秤医药股份有限公司 用于制备取代的1-O-酰基-2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖的方法
JP5776564B2 (ja) * 2012-01-20 2015-09-09 日本精工株式会社 ワーク処理装置、及びワーク処理方法
SG11201406080VA (en) * 2012-03-28 2014-11-27 Fujifilm Corp SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE
EP3184112B1 (en) * 2012-08-13 2020-12-23 FUJIFILM Corporation SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE
JP6245527B2 (ja) * 2014-03-24 2017-12-13 富士フイルム株式会社 チオラン環もしくはチアン環骨格を有する化合物の製造方法

Also Published As

Publication number Publication date
JP2017155031A (ja) 2017-09-07
TW201735931A (zh) 2017-10-16
EP3424509B1 (en) 2020-10-14
EP3424509A1 (en) 2019-01-09
JP6450356B2 (ja) 2019-01-09
HK1257435A1 (zh) 2019-10-18
KR102160866B1 (ko) 2020-09-28
US11382927B2 (en) 2022-07-12
CN108697726A (zh) 2018-10-23
CA3016020A1 (en) 2017-09-08
KR20180104115A (ko) 2018-09-19
CN108697726B (zh) 2021-04-16
US20180360865A1 (en) 2018-12-20
AU2017227280B2 (en) 2019-11-21
CA3016020C (en) 2020-10-27
EP3424509A4 (en) 2019-03-20
WO2017150511A1 (ja) 2017-09-08
RU2715240C1 (ru) 2020-02-26
AU2017227280A1 (en) 2018-09-13
BR112018067808B1 (pt) 2024-01-02
TWI752940B (zh) 2022-01-21

Similar Documents

Publication Publication Date Title
BR112018067808A2 (pt) preparação medicinal líquida
BR112015020302A2 (pt) derivado de pirazol
CL2018003105A1 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos.
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
BR112017024933A8 (pt) Alvocidib produce com a bioavailabilidade aumentada
DOP2016000248A (es) Inhibidores de diacilglicerol aciltransferasa 2
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112016017747A2 (pt) Agente de intensificação de efeito de reabilitação pós lesão de nervo compreendendo derivados de éter de alquila ou sal do mesmo
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
BR112019008239A2 (pt) formulações aquosas, estáveis, injetáveis de capsaicina e uso médicos dos mesmos
BR112016027435A2 (pt) formulação inovadora de meloxicam
BR112022005595A2 (pt) Composto, medicamento, métodos para inibir histona deacetilase 6 e para profilaxia ou tratamento de doença de alzheimer ou paralisia supranuclear progressiva em um mamífero, e, uso de composto
BR112017002796A2 (pt) método de induzir saciedade
BR112020022088A8 (pt) Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2016001763A1 (es) Antagonistas selectivos de nr2b
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CL2018003318A1 (es) Triazoles para la regulación de la homeostasis de calcio intracelular.
BR112015019347A2 (pt) medicamento com sabor de anis
BR112016008901A2 (pt) Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor.
BR112019023817A8 (pt) Composições tópicas e métodos para o tratamento de doenças da pele

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2017, OBSERVADAS AS CONDICOES LEGAIS